ImmunoGen, Inc. (NASDAQ:IMGN) issued financial report for the quarter closed September 30, 2017 and reviewed recent highlights. Mark Enyedy, the CEO and President, expressed that during the third quarter, they advanced on the momentum in the business with remarkable operational execution and by considerably strengthening their capital position.

The details

The CEO of ImmunoGen expressed that the Jazz deal supports the advancement of their early-stage plans in hematological malignancies, and the funds from this deal and the October financing extend their operating runway beyond the anticipated timeframe of the data of FORWARD I, their Phase III registration trial for mirvetuximab.

They are continuing to support FORWARD I along with their FORWARD 2 study assessing mirvetuximab in numerous combination plans, and look forward to showcasing report on IMGN632 and IMGN779 at the ASH Annual Meeting next month and opening the Phase I trial for IMGN632 by year-end. Depending on the progress recorded this year, they will enter 2018 with FORWARD 1 on track to close registration by mid-year, two agents deploying their unique IGN payload in the clinic, a strong balance sheet and, clinical data for mirvetuximab’s prospective role as a combination therapy.

For Q3 2017, ImmunoGen posted revenue of $8.5 million versus $7.7 million for the quarter closed September 30, 2016. The third quarter revenue of 2017 comprised non-cash royalty revenues of $6.5 million, versus non-cash royalty revenues of $6.2 million for the same quarter, a year ago. Revenues for Q3 2017 also comprised research and development support fees of $0.7 million and clinical materials revenue of $1.2 million, as against $1.4 million and $0.1 million, correspondingly, for the comparable quarter in 2016.

There was a decline in operating expenses in Q3 2017 mainly due to reduced third-party service fees and lower personal expenses. For Q3 2017, operating expenses came at $39.6 million versus $46.5 million for the comparable quarter in 2016.

Previous articleZynga Inc (NASDAQ:ZNGA) Appoints Jeff Ryan As Chief People Officer
Next articleWhat Is The Buzz Surrounding OncoSec Medical Inc (NASDAQ:ONCS)?
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.